To evaluate the effectiveness of clinical pharmacist intervention in standardizing the use of antiemetic drugs in tumor treatment by investigating the use of antiemetic drugs in inpatient medical records at a hospital.

Clinical pharmacists reviewed and analyzed the use of antiemetic drugs in the archived medical records of hospitalized patients who received intravenous antitumor treatment from January to April 2023. Following communication with physicians, intervention measures were implemented. The standardization rate and specific usage of antiemetic drugs were assessed at three months and six months post-intervention.

Before intervention, the standardization rate of antiemetic drugs at the hospital was 37.63%. The main issues contributing to non-standard use included inappropriate selection of antiemetic drugs, inappropriate drug selection, inadequate variety, insufficient treatment duration, and unreasonable upgrading of antiemetic regimens. After clinical Pharmacists' intervention, the standardized rate of antiemetic drugs was 63.53% (P<0.001) at three months post-intervention (the intervention group 1), and 86.36% (P<0.001) at six months post-intervention (the intervention group 2). Regarding specific antiemetic drugs, the usage rate of metoclopramide decreased significantly from 44.09% before intervention to 8.24% at three months and 7.95% at six months post-intervention (P<0.05). The usage of olanzapine showed a gradual increase, though the difference was not statistically significant.

Clinical pharmacists achieved significant improvements in the standardization of antiemetic drug use through targeted interventions, thereby reducing nausea and vomiting in tumor patients and achieving favorable intervention outcomes.